… Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results
from the Valsartan Heart Failure Trial (Val-HeFT). Am …

… role of valsartan in left ventricular dysfunction post myocardial … ACE inhibitor use post
myocardial infarction is associated … effective in patients with heart failure post myocardial …

… has led to advances in the treatment of these disorders.[1–3] For … in patients who develop
heart failure or left ventricular systolic dysfunction (LVSD) in the post-myocardial infarction (MI) …

… use of high-dose beta-blocker appears harmful for patients who present in HF. The American
College of Cardiology (ACC)/American Heart … Therefore, valsartan, in the dosages used in …

… treatment with the maximal tolerated dose of valsartan did not exhibit a superior effect on
post-MI LV remodelling compared with low-dose treatment … this study is the use of beta-blockers …

… recommend the use of neurohormonal blocking agents in HF patients [2, 3] … VALsartan In
Acute myocardial iNfarcTion (VALIANT) trial that evaluated the effects of captopril and valsartan…

… Valsartan was used at two doses. 5 and 50 mg/kg. which induced a strong and dose-… model
of heart failure, valsartan administered for a short period antagonized cardiac hypertrophy …

… of the patients to either ramipril or sacubitril/valsartan our … and sacubitril valsartan in relation
to use of MRA Patients were … these patients were as expected at higher risk than patients not …

… The overall findings of Val-HeFT support the use of valsartan as an alternative in heart
failure patients intolerant to ACE inhibitors, but not as an add-on to ACE inhibitor therapy. …

… rate with either use of valsartan compared with captopril. The … signs of heart failure and/or
evidence of left ventricular systolic … in patients with post–myocardial infarction left ventricular …